News Conference News ESC 2024 Trial Challenges Continuation of Oral Anticoagulants During TAVI Todd Neale August 31, 2024
Presentation ESC 2024 Continuation versus Interruption of Oral Anticoagulation during TAVI Presenter: Dirk-Jan van Ginkel August 31, 2024
News Conference News ESC 2023 ESC Focused Update on HF Synthesizes New Trial Data for Practical Use L.A. McKeown September 01, 2023
News Conference News ESC 2023 New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground Caitlin E. Cox August 30, 2023
News Conference News ESC 2022 INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF Michael O'Riordan August 28, 2022
News Conference News ESC 2022 Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke Todd Neale August 28, 2022
News Conference News ESC 2020 Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism Caitlin E. Cox September 04, 2020
News Conference News ESC 2020 VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban L.A. McKeown September 03, 2020
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019
News Conference News ESC 2018 Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR Shelley Wood August 28, 2018
Presentation ESC 2018 ASCEND Randomized placebo-controlled trial of aspirin Presenter: Jane Armitage August 27, 2018
News Conference News ESC 2018 ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients Todd Neale August 26, 2018
News Conference News ESC 2018 MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis Todd Neale August 26, 2018
News Conference News ESC 2017 Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death Yael L. Maxwell September 01, 2017
News Conference News ESC 2017 COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease Todd Neale August 27, 2017
News Opinion Editor's Corner ESC 2017 ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On Shelley Wood August 18, 2017
News Conference News ESC 2016 Reversal Agent for Factor Xa Inhibitors Rapidly Reduces Anticoagulant Effects: ANNEXA-4 Todd Neale August 31, 2016
News Conference News ESC 2016 NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry Michael O'Riordan August 28, 2016